RIGL vs LXRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RIGL · Rigel Pharmaceuticals$39.65 ▼ 13.26%
LXRX · Lexicon Pharmaceuticals$1.78 ▲ 10.56%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RIGL +14.8%
- LXRX +25.4%
Head to head
| Metric | RIGL | LXRX |
|---|---|---|
| Price | $39.65 | $1.78 |
| Change today | ▼ 13.26% | ▲ 10.56% |
| Market cap | $746.61M | $792.52M |
| Return, 3 months | -4.8% | -25.8% |
| Return, year to date | -7.4% | +54.8% |
| Return, 1 year | +12.7% | +42.4% |
| P/E (TTM) | 2.5 | – |
| P/B | 1.7 | 4.8 |
| P/E percentile vs own 5y | 74th | 16th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -22.6% | -97.6% |
| Net profit growth (YoY) | -71.0% | -1,077.1% |
| Gross margin | 91.4% | 99.1% |
| Operating margin | 31.5% | -131.4% |
| Net margin | 116.3% | -147.4% |
| Return on equity | 126.9% | -40.2% |
| Analyst target vs. price | +63.9% | +224.7% |
| Analyst buy share | 50% | 100% |
| RSI (14) | 30 | 61 |
| 30-day volatility | 63.4% | 60.9% |
| Max drawdown, 1 year | -50.1% | -46.2% |
| Trend read | Leaning bearish | Mixed |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LXRX is the largest of the group by market value.
- LXRX has returned the most over the past year.
- RIGL is growing revenue fastest.
- RIGL keeps the most profit per dollar of sales.
- LXRX has been the calmest stock over the last 30 days.